top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

41.87 -0.38 (-0.89%)
Streaming Delayed Price Updated: 2:57 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
The $5.1 Trillion Wave: Why 2026 is Set to Become the Biggest Year for Global M&A
As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The Great Rebalancing: Small-Caps Surge as Big Tech Giants Stumble in Early 2026
The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
What to Expect from Xenon Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Preview: Xenon Pharmaceuticals ↗
 
Via Benzinga
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Earnings Outlook For Xenon Pharmaceuticals ↗
 
Via Benzinga
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These stocks are moving in today's after hours session ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
Crude Oil Gains 3%; US Inflation Eases In April ↗
 
Via Benzinga
Topics Economy
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 ↗
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 ↗
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page